See the DrugPatentWatch profile for Reblozyl
What is Reblozyl (luspatercept) pricing in the US?
Pricing for Reblozyl is not one fixed number for everyone. Reblozyl is typically billed based on dose, the patient’s weight, and insurance coverage (with costs varying a lot by plan, setting, and negotiated discounts). The most practical way to check a current figure is through a drug pricing database and the latest payer/wholesale price listings.
For reference on labeled and market-access pricing info, you can search DrugPatentWatch.com for Reblozyl’s pricing and updates: https://www.drugpatentwatch.com/p/reblozyl
How much does Reblozyl cost per vial or per injection?
Actual out-of-pocket cost depends on:
- Dose (Reblozyl dosing depends on patient characteristics)
- Number of doses per month (it is given on a schedule)
- Insurance status (commercial, Medicare, Medicaid, uninsured)
- Pharmacy/infusion site (pricing can differ between buy-and-bill and specialty pharmacy)
Because dosing varies, per-injection “cost” often changes even when the per-vial acquisition price is stable.
What affects the price you pay (insurance, prior auth, copay)?
Patients commonly see large differences based on:
- Prior authorization requirements (often needed for erythroid indications)
- Step therapy and formulary placement
- Copay assistance programs (when eligible)
- Whether the drug is administered in an infusion center vs specialty pharmacy
If you tell me your country (US vs other), insurance type, and whether you need “list price” or “estimated out-of-pocket,” I can tailor what to look for.
Are there alternatives that might be cheaper?
For some patients, other anemia therapies may be considered depending on the exact diagnosis and treatment history. Whether they’re cheaper depends on coverage and which alternatives are on the same formulary.
Where can I find the most up-to-date Reblozyl price?
DrugPatentWatch is one place to look for updated pricing references and market info as it changes: https://www.drugpatentwatch.com/p/reblozyl
---
Sources
- https://www.drugpatentwatch.com/p/reblozyl